Vanda Fights FDA’s Refusal To Fast-Track Gastro Drug Review

Overview


Paul Hughes, Andrew Lyonsberg and Alex Boota are featured in Law360 for representing Vanda Pharmaceuticals in its complaint to the FDA for the denial of Vanda’s bid for fast-tracking review of its treatment: tradipitant.